CLK-peptide and SLK-peptide
AssigneeNew York University
InventorsPeter C. Brooks, Jennifer Roth, Abebe Akalu
Life of this patent
Estimating the term…
Abstract
The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo. The invention further describes methods for treating tumors using said antagonists in combination with radiation therapy and therapies comprising the antagonists and radiation treatment.
Claims25
A method for detecting a denatured collagen type-IV binding site in a patient having a disease or condition that is characterized by or associated with denaturation of collagen type-IV, comprising:
- administering a denatured collagen type-IV selective antagonist to the patient;
- and
- detecting the selective antagonist that is bound to denatured collagen type-IV in the patient;
- wherein the denatured collagen type-IV selective antagonist is a peptide comprising the core amino acid sequence referenced as SEQ ID NO:
- 1, and wherein said detecting is performed using a diagnostic imaging technique selected from the group consisting of magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT).
A method for detecting angiogenesis in a tissue sample, comprising:
- contacting the tissue sample with a denatured collagen type-IV selective antagonist;
- and
- detecting the selective antagonist that is bound to denatured collagen type-IV in the tissue sample;
- wherein the denatured collagen type-IV selective antagonist is a peptide comprising the core amino acid sequence referenced as SEQ ID NO:
- 1, and wherein said detecting is performed indirectly using an antibody assay.
A method for detecting a denatured collagen type-IV binding site in a tissue sample from a patient having a disease or condition that is characterized by or associated with denaturation of collagen type-IV, comprising:
- contacting a denatured collagen type-IV selective antagonist to the tissue sample;
- and
- detecting the selective antagonist that is bound to denatured collagen type-IV in the tissue sample;
- wherein the denatured collagen type-IV selective antagonist is a peptide comprising the core amino acid sequence referenced as SEQ ID NO:
- 1, and wherein said detecting is performed indirectly using an antibody assay.
A method of detecting tumor cell adhesion in a patient comprising:
- administering a denatured collagen type-IV selective antagonist to the patient, and
- detecting the selective antagonist that is bound to denatured collagen type-IV in the patient;
- wherein the denatured collagen type-IV selective antagonist is a peptide comprising the core amino acid sequence referenced as SEQ ID NO:
- 1, and wherein said detecting is performed using a diagnostic imaging technique selected from the group consisting of magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT).
Dependencies are inferred from the claim text.